A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

PURPOSE: To evaluate the safety and tolerability in phase I first-in-human combination therapy with pexidartinib, an inhibitor of colony-stimulating factor-1 receptor, and sirolimus, an mTOR inhibitor, to target tumor-associated macrophage (TAM) polarization in soft tissue sarcomas (STS). PATIENTS A...

Descripción completa

Detalles Bibliográficos
Autores principales: Manji, Gulam A., Van Tine, Brian A., Lee, Shing M., Raufi, Alexander G., Pellicciotta, Ilenia, Hirbe, Angela C., Pradhan, Jaya, Chen, Andrew, Rabadan, Raul, Schwartz, Gary K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530953/
https://www.ncbi.nlm.nih.gov/pubmed/34321280
http://dx.doi.org/10.1158/1078-0432.CCR-21-1779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530953/
https://www.ncbi.nlm.nih.gov/pubmed/34321280
http://dx.doi.org/10.1158/1078-0432.CCR-21-1779

Ejemplares similares